Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: the Swiss HIV Cohort Study

Bucher, H. C.; Bichsel, M.; Taffe, Patrick; Furrer, Hansjakob; Telenti, A.; Hirschel, Bernard; Weber, R.; Bernasconi, Enos; Vernazza, P.; Minder, C.; Battegay, M.

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: the Swiss HIV Cohort Study
Authors		Bucher, H. C. Bichsel, M. Taffe, Patrick Furrer, Hansjakob Telenti, A. Hirschel, Bernard Weber, R. Bernasconi, Enos Vernazza, P. Minder, C. Battegay, M. show all authors [1 - 11]
Published in		HIV Medicine. 2002, vol. 3, no. 4, p. 247-253
Abstract		OBJECTIVES: To compare the response to ritonavir (RTV) plus saquinavir (SQV) with single protease inhibitor (PI) therapies among PI-naive HIV-1 infected individuals. METHODS: Response to treatment was analysed according to the intent-to-treat principle in a prospective observational cohort study of 177 patients who between May 1995 and March 2000 started a double PI therapy with RTV and SQV (nonboosting dosages) plus at least one nucleoside reverse transcriptase inhibitor (NRTI) and 2,214 patients with a single PI therapy plus two NRTIs. We used survival analysis and Cox's proportional hazard regression methods. The primary endpoint was the time to a plasma viral load of < 400 copies/mL. Secondary endpoints were taken as a gain in the CD4 count of >100 cells/microL, and change of initial PI for any reason. RESULTS: Baseline characteristics in both treatment groups were balanced. Median follow-up in both groups was 10.4 months. Time to an HIV-1 viral load of < 400 copies/mL and an increase in the CD4 count of >100 x 10(6) cells/L was shorter for RTV plus SQV compared with single PI regimens (log rank test for each endpoint P < 0.05). The adjusted hazard ratios of RTV plus SQV compared with single PI regimens were 1.21 (95% confidence interval 0.99-1.47) for achieving an HIV-1 viral load of < 400 copies/mL, 1.12 (0.88-1.42) for an increase in the CD4 count of > 100 cells/microL, and 0.90 (0.73-1.11) for change of first PI regimen. CONCLUSIONS: Treatment with RTV plus SQV compared with single PI regimens appeared to give similar results for virological or immunological response.
Keywords		Adolescent — Adult — Aged — Aged, 80 and over — CD4 Lymphocyte Count — Cohort Studies — Drug Therapy, Combination — Female — Follow-Up Studies — HIV Infections/ drug therapy — HIV Protease Inhibitors/ administration & dosage — Humans — Male — Middle Aged — Prospective Studies — RNA, Viral/blood — Reverse Transcriptase Inhibitors/ administration & dosage — Ritonavir/ administration & dosage — Saquinavir/ administration & dosage — Viral Load
Identifiers		DOI: 10.1046/j.1468-1293.2002.00113.x PMID: 12444942
Full text		Article - Limited access to UNIGE Other version: http://www3.interscience.wiley.com/journal/118963392/abstract
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine interne des spécialités
Citation (ISO format)		BUCHER, H. C. et al. Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: the Swiss HIV Cohort Study. In: HIV Medicine, 2002, vol. 3, n° 4, p. 247-253. https://archive-ouverte.unige.ch/unige:7124